Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives $55.13 Consensus Target Price from Analysts

by · The Cerbat Gem

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) have earned an average recommendation of “Moderate Buy” from the seventeen brokerages that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $55.13.

TNDM has been the topic of a number of recent analyst reports. The Goldman Sachs Group assumed coverage on Tandem Diabetes Care in a research note on Friday, October 4th. They set a “neutral” rating and a $46.00 price target on the stock. Piper Sandler reissued an “overweight” rating and issued a $55.00 price target (up from $50.00) on shares of Tandem Diabetes Care in a research note on Friday, August 2nd. Royal Bank of Canada began coverage on Tandem Diabetes Care in a report on Wednesday, October 2nd. They issued an “outperform” rating and a $65.00 price target for the company. Robert W. Baird increased their price objective on shares of Tandem Diabetes Care from $36.00 to $39.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Finally, Morgan Stanley restated an “equal weight” rating and issued a $45.00 target price on shares of Tandem Diabetes Care in a report on Monday, September 23rd.

Read Our Latest Stock Report on Tandem Diabetes Care

Tandem Diabetes Care Trading Down 1.7 %

Shares of TNDM stock opened at $33.54 on Friday. The company has a market capitalization of $2.20 billion, a price-to-earnings ratio of -16.05 and a beta of 1.33. The company has a current ratio of 3.05, a quick ratio of 2.38 and a debt-to-equity ratio of 1.31. The firm has a 50-day moving average price of $41.71 and a 200 day moving average price of $41.97. Tandem Diabetes Care has a twelve month low of $13.82 and a twelve month high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The medical device company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. The business had revenue of $221.90 million during the quarter, compared to analyst estimates of $205.63 million. Tandem Diabetes Care had a negative net margin of 17.15% and a negative return on equity of 41.54%. The company’s revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.30) earnings per share. Research analysts forecast that Tandem Diabetes Care will post -1.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TNDM. ORG Wealth Partners LLC purchased a new stake in shares of Tandem Diabetes Care in the third quarter worth about $30,000. ORG Partners LLC purchased a new position in Tandem Diabetes Care in the 2nd quarter worth approximately $31,000. Headlands Technologies LLC acquired a new stake in Tandem Diabetes Care in the first quarter valued at approximately $35,000. MCF Advisors LLC raised its stake in shares of Tandem Diabetes Care by 79.3% during the first quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after purchasing an additional 445 shares during the period. Finally, Waldron Private Wealth LLC acquired a new position in shares of Tandem Diabetes Care during the third quarter worth $50,000.

Tandem Diabetes Care Company Profile

(Get Free Report

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

Featured Articles